Newsletter
Sign Up And Receive Our Latest Promotions!
Thank you! Your submission has been received!
.svg){kind=small}
Access insights from Real-World Evidence in Ophthalmology
Achieve your goals faster with more disease insights in Ophthalmology including Geographic Atrophy, Neovascular Age-related Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema and Inherited Retinal Diseases
By unlocking the full potential of real world data with enriched insights into disease biomarkers, patient populations and treatment trends, we strive to change the way Pharma and Life Sciences tackle strategic decisions in development to clinical research to commercialization.
225K+
High-quality patient records with insights into clinical factors and disease biomarkers to date
10+
Algorithms for retinal layer segmentation, fluid analysis, disease biomarkers and prediction analysis
30+
Peer-reviewed publications on using our models in real world evidence generation
Benefits of our Real World Evidence Insights
across the entire Pharma value chain
Clinical Development
- Identify unmet needs to design better research
- Improve trial design with specific inclusion and exclusion criteria
- Optimize patient selection based on biomarkers influencing disease outcomes
.png)
HEOR
- Demonstrate value to payers
- Compare study data with real world outcomes
- Enable value-based pricing
Commercialization
- Improve product positioning and messaging
- Gain better market knowledge, treatment trends and factors influencing decisions to treatment
- Design patient services and education
Why choose our Real-World Evidence Data packages?
We are bringing together data, analytical tools and support to help your company achieve their goals,
faster and with more disease insights than ever before.
Collaborating with top-notch clinical networks globally
RetinAI collaborates with large-scale clinical networks dedicated to delivering exceptional care to their patients. As a result, RetinAI accesses regulatory-grade real world data through partnerships to generate quality-driven real world evidence.
In 2023, RetinAI partnered with Retina Consultants of America,
the largest U.S. retina provider,
to create insights for advancing healthcare in Ophthalmology.
In 2023, RetinAI partnered with Retina Consultants of America,
the largest U.S. retina provider,
to create insights for advancing healthcare in Ophthalmology.
Value across the Ophthalmology product lifecycle
RetinAI’s customized real-world evidence solutions can shorten timelines, minimize risks in development, inform study design and identify target patients.
Pharma decision makers in research, development and commercial rely on real world evidence to improve and enhance their data decision workflow.
Pharma decision makers in research, development and commercial rely on real world evidence to improve and enhance their data decision workflow.
Translating real world data to actionable insights for decisions
Our team of data and bio statistician experts integrate best-in-class data management practices, advanced analytics like AI and machine-learning, and comply with the highest measures for data security and privacy, to ensure the highest quality standards in RWE generation needed for decisions, at-scale.
RetinAI’s Discovery platform is 510K-cleared, MDR-certified and complies with HIPAA, GDPR and PIPEDA.
RetinAI’s Discovery platform is 510K-cleared, MDR-certified and complies with HIPAA, GDPR and PIPEDA.
*Disclaimer
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.
